The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The new assay consolidates screening for four major viral threats into a single workflow
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
Subscribe To Our Newsletter & Stay Updated
